McKesson Announces Management Changes in Pharmaceutical Solutions and Medical-Surgical Solutions

-- John Figueroa, president of Retail National Accounts for U.S. Pharmaceutical Distribution, becomes president, U.S. Pharmaceutical Distribution, a position previously filled by Julian in addition to his other responsibilities.

-- Gary Muensterman, president, McKesson Medical-Surgical, becomes senior vice president, Corporate Strategy and Business Development, reporting to Marc Owen, executive vice president, Corporate Strategy and Business Development.

-- Brian Tyler, president, McKesson Specialty Pharmaceutical, becomes president, McKesson Medical-Surgical.

-- Patrick Blake, president, Customer Operations for U.S. Pharmaceutical Distribution, becomes president, McKesson Specialty Pharmaceutical, McKesson Pharmacy Systems and Automated Prescription Systems.

"Over the past six years, John, Gary, Brian and Pat have been keycontributors on the team that has helped drive the growth and marketleadership of McKesson's supply businesses," said Julian. "They willnow have the opportunity to apply their experience and skill sets innew roles that should help drive value creation for McKesson'scustomers, employees and shareholders while building a deeper benchfor the company. I am looking forward to continuing to work with themand other McKesson business leaders to execute and grow theirbusinesses while increasing my focus on strategic opportunities tocreate additional shareholder value."

Claudio Bussandri, president, McKesson Canada, Emad Rizk,president of McKesson Health Solutions, the company's payor business,and Eleonore Saenger, president of McKesson Medication Management,continue to report to Julian.

"Paul and his team have delivered market-leading performance inour U.S. and Canadian pharmaceutical distribution businesses, and wecontinue to gain market momentum in our medical-surgical business,"said John H. Hammergren, chairman and chief executive officer ofMcKesson. "They have improved our quality of service, relationshipswith suppliers and cost structure by developing sound strategies whichthey executed flawlessly. These new assignments are designed tocontinue our growth and value creation while strengthening thecompany's leadership for the future."

Figueroa joined McKesson in 1997 as a sales executive for McKessonHealth Systems. He was later named regional vice president for theWestern Region of U.S. Pharmaceutical Distribution. In 2002, he becamepresident, Retail National Accounts, a position in which hestrengthened McKesson's relationships and market share among retaildrug chains, mass merchandisers and food-drug retailers. Under hisleadership, this business increased from $24 billion to $44 billionannually. He was also responsible for the company's retail andinstitutional packaging operations. He was previously a salesexecutive at Baxter International.

Muensterman joined McKesson in 2000 as executive vice president,McKesson Carrollton Financial Services, the company's centralizedfinancial services operation, where over a two and one-half-yearperiod he significantly improved the quality and effectiveness ofthese operations. In 2002, he became president of McKessonMedical-Surgical. Prior to McKesson, he headed the financial serviceoperations of Allegiance Corporation.

Tyler joined McKesson in 1997 in business development for McKessonHealth Systems. From 2000 to 2003, he was senior vice president,McKesson Supply Solutions. In 2003, he was named president, McKessonSpecialty Pharmaceutical, which has grown significantly under hisleadership. Prior to McKesson, he was an industry consultant.

Blake joined McKesson in 1996 as a sales executive for McKessonHealth Systems. In 1999, he was named president, McKesson HealthSystems, which continues to report to him since he became president,Customer Operations in 2001. Under his leadership, McKesson'sinstitutional pharmaceutical distribution business has grown from $3billion to $16 billion. He has also led a successful program tocross-sell retail automation and pharmacy systems to independentpharmacy customers for which he is also responsible. Prior toMcKesson, he was a sales executive with Baxter International.

About McKesson

McKesson Corporation (NYSE:MCK), currently ranked 15th on theFORTUNE 500, is a healthcare services and information technologycompany dedicated to helping its customers deliver high-qualityhealthcare by reducing costs, streamlining processes and improving thequality and safety of patient care. Over the course of its 173-yearhistory, McKesson has grown by providing pharmaceutical andmedical-surgical supply management across the spectrum of care;healthcare information technology for hospitals, physicians, homecareand payors; hospital and retail pharmacy automation; and services formanufacturers and payors designed to improve outcomes for patients.For more information, visit us at www.mckesson.com.

Risk Factors

Except for historical information contained in this press release,matters discussed may constitute "forward-looking statements", withinthe meaning of Section 27A of the Securities Act of 1933 and Section21E of the Securities Exchange Act of 1934, that involve risks anduncertainties that could cause actual results to differ materiallyfrom those projected, anticipated or implied. These statements may beidentified by their use of forward-looking terminology such as"believes", "expects", "anticipates", "may", "should", "seeks","approximates", "intends", "plans", "estimates" or the negative ofthese words or other comparable terminology. The most significant ofthese risks and uncertainties are described in the company's Form10-K, Form 10-Q and Form 8-K reports filed with the Securities andExchange Commission and include, but are not limited to: theresolution or outcome of pending shareholder litigation regarding the1999 restatement of our historical financial statements; the changingU.S. healthcare environment, including the impact of potential futuremandated benefits; changes in private and governmental reimbursementor in the delivery systems for healthcare products and services;governmental efforts to regulate the pharmaceutical supply chain;changes in pharmaceutical and medical-surgical manufacturers' pricing,selling, inventory, distribution or supply policies or practices;changes in customer mix; substantial defaults in payment or a materialreduction in purchases by large customers; challenges in integratingand implementing the company's software and software system products,or the slowing or deferral of demand for these products; the company'sability to success identify, consummate and integrate strategicacquisitions; changes in generally accepted accounting principles(GAAP); foreign currency fluctuations; and general economicconditions. The reader should not place undue reliance onforward-looking statements, which speak only as of the date they aremade. The company assumes no obligation to update or revise any suchstatements, whether as a result of new information or otherwise.